PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

    Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

    Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M4PxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOEKwNlQh|ryP NXviVpRMW0GQR1XS
UACC-893 NGSwSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwMUm4PFYh|ryP NHLzc4RUSU6JRWK=
A427 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\yTWM2OD13LkeyOVY4KM7:TR?= Mkj0V2FPT0WU
OCUB-M NX61eVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTZwNk[xNFIh|ryP MX\TRW5ITVJ?
SW684 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdwNUKyOlgh|ryP MlHwV2FPT0WU
SK-LMS-1 NHLzUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLTTWM2OD17LkCxN|AzKM7:TR?= NWHnZWdPW0GQR1XS
CP50-MEL-B M4fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\uRotLUUN3ME25MlMxPDF7IN88US=> M3y3U3NCVkeHUh?=
NCI-H1651 NEnZWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3EW|ZOUUN3ME2xNE4xOjd4IN88US=> M2TQOnNCVkeHUh?=
ABC-1 M2DoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FTWM2OD1zMD6xNFM4KM7:TR?= MVnTRW5ITVJ?
OE19 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;VTWM2OD1zMD6xO|M{KM7:TR?= NIHuWFlUSU6JRWK=
DSH1 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHWTWM2OD1zMD64PFc6KM7:TR?= MV7TRW5ITVJ?
SW13 M3T6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\seWlEPTB;MUGuPVMyQSEQvF2= MXPTRW5ITVJ?
MDA-MB-453 NUPGS2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne3TWM2OD1zMj6xOlA{KM7:TR?= NWXCeWdMW0GQR1XS
647-V MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4N4k5UUN3ME2xNk4{PTh{IN88US=> MlTEV2FPT0WU
NCI-H2342 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTUTFZDUUN3ME2xNk4{QTl3IN88US=> MmHMV2FPT0WU
LB2241-RCC M3nYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQTI9KSzVyPUGyMlU4PzlizszN Mlm4V2FPT0WU
UACC-257 NWDWVXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT2TWM2OD1zMz60OFU{KM7:TR?= M{XaR3NCVkeHUh?=
NCI-H661 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OD1zMz62OFQ6KM7:TR?= NF;SfXhUSU6JRWK=
FADU MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P1bWlEPTB;MUOuOlk6OiEQvF2= MVnTRW5ITVJ?
A2780 NXHyUpllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHobY9PUUN3ME2xN{45ODRzIN88US=> MUfTRW5ITVJ?
NCI-H1793 NHPhUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi2VmlVUUN3ME2xOE41ODh3IN88US=> NHO0XGhUSU6JRWK=
TE-8 NUPl[5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLvPFRnUUN3ME2xOU4{PDZ3IN88US=> M4XiZXNCVkeHUh?=
HGC-27 NHHOVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\hUoh5UUN3ME2xOk4yPjR2IN88US=> M1THcnNCVkeHUh?=
MMAC-SF NIT0bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLiTWM2OD1zNz6zO|I4KM7:TR?= NIDuWlJUSU6JRWK=
Calu-6 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tw[2lEPTB;MUiuNVUyOyEQvF2= MljPV2FPT0WU
HUTU-80 NXfHUnNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXjTWM2OD1zOD6zPVU6KM7:TR?= MVPTRW5ITVJ?
SAS MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\SWWlEPTB;MUiuOlQ2PSEQvF2= NHXxN|ZUSU6JRWK=
IST-MES1 NVXSZWxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnTfHJKSzVyPUG4MlY2ODhizszN Mk\FV2FPT0WU
C3A NH7xWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HFXGlEPTB;MUiuO|kyQSEQvF2= NGPNe5FUSU6JRWK=
ES3 NFO2boRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrKbnpKSzVyPUG4Mlg{PjRizszN MlnJV2FPT0WU
HSC-2 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLB[lZKSzVyPUG5MlY2PDFizszN NUO4b49[W0GQR1XS
T47D MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJyLkG0PFUh|ryP NVPHNFRMW0GQR1XS
EW-7 NWX2em1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJyLki1PFgh|ryP MnXmV2FPT0WU
LN-405 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTsTWM2OD1{MD64PVY2KM7:TR?= M4DHbXNCVkeHUh?=
U031 NWfXXmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlRXhKSzVyPUKxMlQ5ODJizszN NUfhVm11W0GQR1XS
A549 NGK0OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorVTWM2OD1{MT64OFkyKM7:TR?= MUTTRW5ITVJ?
RMG-I MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ{LkK2Olgh|ryP M2TJZXNCVkeHUh?=
BT-474 NGHqUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXBPJlKSzVyPUKyMlY2PTFizszN MlrIV2FPT0WU
NB69 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfr[ohUUUN3ME2yN{4yPTJizszN NFXrVXNUSU6JRWK=
NB7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ2LkG4PEDPxE1? NH7n[W9USU6JRWK=
HCC1569 M1fsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni5TWM2OD1{ND62NVI2KM7:TR?= MkPwV2FPT0WU
MEL-JUSO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ2Lk[5NFgh|ryP M4LVOHNCVkeHUh?=
MDA-MB-175-VII MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;JUXRsUUN3ME2yOU4zPTF5IN88US=> NXHK[lRRW0GQR1XS
HCC1419 NGTDfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvZPJZKSzVyPUK1MlYxODNizszN NHj6Z5RUSU6JRWK=
Ca9-22 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpOHJKSzVyPUK1MlY1OzJizszN Mn3hV2FPT0WU
KGN M{DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnGTWM2OD1{NT63OVQ4KM7:TR?= MW\TRW5ITVJ?
LB373-MEL-D MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi5dHRKSzVyPUK2MlE6OzhizszN MUfTRW5ITVJ?
NCI-H1755 NY\mbGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYflNIxbUUN3ME2yOk45QDRzIN88US=> NETncGJUSU6JRWK=
D-423MG NV\GUWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ5LkC3NVUh|ryP M2TJcnNCVkeHUh?=
DK-MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXpbZR2UUN3ME2yPE44QDR4IN88US=> MYfTRW5ITVJ?
NCI-H1623 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17mcGlEPTB;MkiuPFM1OiEQvF2= MXXTRW5ITVJ?
KU-19-19 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3QZphPUUN3ME2yPE46QTVizszN NXfNUmhFW0GQR1XS
C-33-A MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LFUmlEPTB;MkmuNlE6QCEQvF2= MV7TRW5ITVJ?
SCC-4 NH;5ZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7FdJBKSzVyPUOwMlM{PTRizszN NUTqcphiW0GQR1XS
MG-63 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNyLkW5PVQh|ryP MUDTRW5ITVJ?
LNCaP-Clone-FGC NXTaWpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS3dWhuUUN3ME2zNU41QTJzIN88US=> MYHTRW5ITVJ?
CAPAN-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nMN2lEPTB;M{GuOVI5PiEQvF2= NVfjclNIW0GQR1XS
GI-ME-N MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNNmlEPTB;M{GuOVM2OyEQvF2= M2fJUXNCVkeHUh?=
RERF-LC-MS NGX4PFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\1ZlFKSzVyPUOyMlY4PDdizszN NGP3cGVUSU6JRWK=
KLE NUm3WFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN|LkSzN|Qh|ryP MXHTRW5ITVJ?
KNS-81-FD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\IPI5KSzVyPUOzMlUxODhizszN MYDTRW5ITVJ?
DOK M37tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn2doo{UUN3ME2zOE43PjF{IN88US=> M1TPXXNCVkeHUh?=
ACHN MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfITWM2OD1|NT6xOVg5KM7:TR?= NUj1eoxsW0GQR1XS
KYSE-520 NG\uVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD1|NT6yN|YyKM7:TR?= M1L0XHNCVkeHUh?=
SBC-5 M2H6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfEbos{UUN3ME2zOU42OTF4IN88US=> Mln0V2FPT0WU
NCI-H28 NILLTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXhTWM2OD1|NT62Olk2KM7:TR?= NYKyUVduW0GQR1XS
ES7 NFfkfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yTWM2OD1|Nj6yNlQ6KM7:TR?= MnLVV2FPT0WU
A172 NV2zSphnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XMWWlEPTB;M{[uOFE5PyEQvF2= MYHTRW5ITVJ?
UM-UC-3 NUHQd4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG1TWM2OD1|Nz64O|Q3KM7:TR?= MmrrV2FPT0WU
LXF-289 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN6LkCwOFch|ryP M3H1cXNCVkeHUh?=
KP-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN6LkS3N|kh|ryP Ml:0V2FPT0WU
TE-1 NWDRXYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjYUIxiUUN3ME2zPU43PTh7IN88US=> MV;TRW5ITVJ?
G-402 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KwRmlEPTB;NECuNFYyKM7:TR?= NFK0bXBUSU6JRWK=
786-0 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HjO2lEPTB;NECuPVA6PiEQvF2= NYnPUJM6W0GQR1XS
K5 NFzLT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTRzLkO2PFYh|ryP MU\TRW5ITVJ?
SK-N-DZ MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPsTWM2OD12MT6zPFI{KM7:TR?= NVTNe3F{W0GQR1XS
OVCAR-4 M1Pyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPXemUzUUN3ME20NU44PTZ6IN88US=> MUXTRW5ITVJ?
T84 NUGzdVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33VZ2lEPTB;NEKuNVI3OyEQvF2= NGXDR|BUSU6JRWK=
GCIY MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTR|LkC4NFMh|ryP NEXWU|hUSU6JRWK=
BB49-HNC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTyTWM2OD12Mz6zN|Q5KM7:TR?= MofxV2FPT0WU
SNU-C2B NY\hNINxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HqNWlEPTB;NEOuOlQ{PiEQvF2= NYTXOZE4W0GQR1XS
TE-6 M1naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTtTWM2OD12Mz64PFk1KM7:TR?= NVLvT5R7W0GQR1XS
23132-87 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXZeY44UUN3ME20OE4zQTd6IN88US=> M4L3bHNCVkeHUh?=
DMS-53 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjybnVKSzVyPUS0MlM{QDRizszN MlfNV2FPT0WU
ONS-76 NF6z[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPRe4UyUUN3ME20OE44PjZzIN88US=> MkTFV2FPT0WU
DMS-273 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fpR2lEPTB;NESuPVQ{KM7:TR?= MlXLV2FPT0WU
COLO-824 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR3Lki3O|Uh|ryP M{Ht[XNCVkeHUh?=
DMS-114 M4LsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3G[pVSUUN3ME20OU45QTJ5IN88US=> NYOwWHlDW0GQR1XS
YKG-1 NWjnWXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGezS|NKSzVyPUS2MlA{PTVizszN M3rMeHNCVkeHUh?=
RH-18 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfiOGRKSzVyPUS2MlM4OzNizszN MmjDV2FPT0WU
NCI-H1355 M3Pi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfvSmpKSzVyPUS2MlYyQCEQvF2= NF\KdmJUSU6JRWK=
NCI-H2170 NU\QW5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR5Lke1PFQh|ryP M{XxZXNCVkeHUh?=
OC-314 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\XT2g6UUN3ME20O{45PDd6IN88US=> MYDTRW5ITVJ?
NCI-H2030 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPk[lFoUUN3ME20O{45QTB4IN88US=> Ml\tV2FPT0WU
22RV1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7UTWM2OD12Nz65NFE2KM7:TR?= NEHQc|ZUSU6JRWK=
G-401 NUHPbmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;PeWlEPTB;NEiuOFQyPSEQvF2= M3XmRnNCVkeHUh?=
YAPC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR7LkiwO|Mh|ryP M3HFNnNCVkeHUh?=
SW1573 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVyLkK0N|Uh|ryP MULTRW5ITVJ?
COLO-792 NYrzVIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD13MD62NlM4KM7:TR?= M{jzTHNCVkeHUh?=
KNS-62 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXUZmtOUUN3ME21NE44PTB6IN88US=> M{W1PHNCVkeHUh?=
NB5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LINGlEPTB;NUGuOFUxQSEQvF2= NX\WWJc{W0GQR1XS
CP66-MEL NGD2bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknMTWM2OD13MT62OFA5KM7:TR?= NVS3PVB{W0GQR1XS
CaR-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTV{LkC2NFYh|ryP MX;TRW5ITVJ?
CAL-54 M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTV{LkGxNFIh|ryP NET1[5dUSU6JRWK=
8305C M{TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLHTWM2OD13Mj6zNVUh|ryP MmOxV2FPT0WU
Calu-3 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LPZ2lEPTB;NUKuN|c{OyEQvF2= MkDDV2FPT0WU
AU565 M1XDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknuTWM2OD13Mj61OVA6KM7:TR?= Ml;rV2FPT0WU
CW-2 M3SwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTV{Lki2OVQh|ryP NXS1VI81W0GQR1XS
BEN NED0PJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULac212UUN3ME21N{44QDZ{IN88US=> NWH5cW1xW0GQR1XS
NCI-H1975 M4XlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1TWM2OD13Mz64PVY3KM7:TR?= MnrOV2FPT0WU
HCT-116 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUftfG94UUN3ME21OE4xOzJ5IN88US=> NYfQNWpVW0GQR1XS
SH-4 NG\NcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD13ND6xN|gh|ryP MVjTRW5ITVJ?
NCI-H1693 M3\XVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTV2LkKxNFMh|ryP MkXjV2FPT0WU
BPH-1 NXfSZWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftO2lEPTB;NUWuNlg6OiEQvF2= NIjFe4lUSU6JRWK=
CAMA-1 NWLsVJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTV3LkixNVYh|ryP MWHTRW5ITVJ?
A388 M4OzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTV4LkC5PFUh|ryP NF\pPWxUSU6JRWK=
C2BBe1 NF\DR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNbpBqUUN3ME21Ok4zPjN2IN88US=> NX;VZ45IW0GQR1XS
GAMG M{KyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTV4LkW5OVUh|ryP M4PGRnNCVkeHUh?=
MKN28 NHPvSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vhR2lEPTB;NU[uPFAyOyEQvF2= NYLIPVZVW0GQR1XS
VA-ES-BJ NVHYNIVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DiPGlEPTB;NU[uPFc1PSEQvF2= NX\j[3lXW0GQR1XS
HuCCT1 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1NVdsUUN3ME21O{4xPDl{IN88US=> MW\TRW5ITVJ?
BFTC-905 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:wWGlEPTB;NUeuNlg6QCEQvF2= MXHTRW5ITVJ?
LS-123 M2DpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTV5LkW2Olgh|ryP M4q0OnNCVkeHUh?=
LB996-RCC M2LXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTV6LkCyPFch|ryP MYTTRW5ITVJ?
NCI-H1048 NFexTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTV6LkKxPFgh|ryP NGr1O|hUSU6JRWK=
COR-L105 NF7YZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DwNWlEPTB;NUiuO|M{PyEQvF2= NFy2RnBUSU6JRWK=
OVCAR-8 NG\zN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T6TGlEPTB;NUmuNVcyPiEQvF2= MVPTRW5ITVJ?
SK-N-FI MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNUoxKSzVyPUW5MlMzODdizszN M4\iXXNCVkeHUh?=
MES-SA NEOzZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\HfZFKSzVyPUW5MlQ2ODlizszN MYrTRW5ITVJ?
SCC-9 NXHoZoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPrXJVrUUN3ME21PU41PzV|IN88US=> NIX2bG1USU6JRWK=
EFO-27 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTV7Lkm0N{DPxE1? NXjaNnJMW0GQR1XS
GT3TKB MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZyLk[wOFgh|ryP MU\TRW5ITVJ?
HCC38 NVXENIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK1TWM2OD14MT60N|c6KM7:TR?= NWToeW1oW0GQR1XS
MLMA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132RmlEPTB;NkGuOlE3OyEQvF2= MWXTRW5ITVJ?
D-566MG NVyyTVlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj5T3ZKSzVyPU[zMlUzOjRizszN MVHTRW5ITVJ?
SF295 NHzTdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZ|Lk[2OVUh|ryP MXnTRW5ITVJ?
ES4 M37nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEewO|NKSzVyPU[0MlQ4OTlizszN MXjTRW5ITVJ?
CAKI-1 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZ2LkW3NlEh|ryP MoXSV2FPT0WU
OAW-28 NGH0ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THVWlEPTB;NkSuPVY1PyEQvF2= NGj3UWRUSU6JRWK=
NCI-H460 M2C1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofUTWM2OD14NT6wPFk4KM7:TR?= NF3CdJRUSU6JRWK=
JAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rw[mlEPTB;NkWuOVUyPiEQvF2= MYnTRW5ITVJ?
SNU-449 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfuTWM2OD14NT63OlE3KM7:TR?= NIDMcVlUSU6JRWK=
D-392MG MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rJZWlEPTB;NkWuPVQ{PCEQvF2= M2jleHNCVkeHUh?=
EW-22 NVXMW2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZ4LkO5OUDPxE1? MkLCV2FPT0WU
GCT MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3eFZnUUN3ME22O{4xPDR|IN88US=> NVeycJo5W0GQR1XS
NOS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD14Nz62PFY4KM7:TR?= MXTTRW5ITVJ?
RH-1 M2LtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZ6LkW1OVkh|ryP M3i5bnNCVkeHUh?=
HuH-7 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHxTWM2OD14OT6xNFAzKM7:TR?= NW\ESpdiW0GQR1XS
NUGC-3 M2XVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSzTWM2OD15MD65OlQ1KM7:TR?= Mlz1V2FPT0WU
IST-SL1 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHsXZdwUUN3ME23NU4zOzJ2IN88US=> NFXtb41USU6JRWK=
SHP-77 M1Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXOe21EUUN3ME23Nk4yOTlizszN MnXQV2FPT0WU
SW1116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvGTWM2OD15Mj6xOFA4KM7:TR?= MYTTRW5ITVJ?
LK-2 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HzSmlEPTB;N{KuPFYyOiEQvF2= NVzjdZhPW0GQR1XS
U-2-OS MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTd|LkG4Nlgh|ryP M2rMfXNCVkeHUh?=
KYSE-150 NYjaRnVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTd|Lk[xNVgh|ryP MkD1V2FPT0WU
U251 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxcWlEPTB;N{OuPFE3QCEQvF2= Mn\lV2FPT0WU
HT-1080 NUjWTokxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjMXYpFUUN3ME23OE4zPTd2IN88US=> NYrG[|JnW0GQR1XS
NCI-H1437 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTd2Lk[zNlYh|ryP NVHvSYtMW0GQR1XS
HPAF-II NV;odYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLJOWN{UUN3ME23OE43PDF3IN88US=> MoXOV2FPT0WU
Becker NYTa[GFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXuc2VKSzVyPUe1MlEyODVizszN MWTTRW5ITVJ?
PANC-10-05 NW\FWHc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j5OmlEPTB;N{WuNlg3PSEQvF2= MUHTRW5ITVJ?
TYK-nu NEn0PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXoZXZ5UUN3ME23OU4{OTB{IN88US=> NU\l[4Z1W0GQR1XS
SKG-IIIa NFnWSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTKWGFKSzVyPUe1MlM{PDFizszN NEPSNVRUSU6JRWK=
NCI-H1993 NGXmOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHjNIFKSzVyPUe1Mlc{QTdizszN MWLTRW5ITVJ?
S-117 M1z2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvSXoVVUUN3ME23OU44PTVizszN MYPTRW5ITVJ?
HuO9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\OeoZKSzVyPUe2MlAxPDhizszN MYHTRW5ITVJ?
CAL-51 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPyZ4R4UUN3ME23Ok4yODB4IN88US=> M{XIPHNCVkeHUh?=
BT-20 M37YPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17CZWlEPTB;N{[uNlE3QCEQvF2= MoqzV2FPT0WU
LB831-BLC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPKSFJKSzVyPUe2MlMzOTdizszN MV\TRW5ITVJ?
LB1047-RCC NEj3emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTd4Lke2NVkh|ryP M2PFWHNCVkeHUh?=
ES8 M37qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELs[mNKSzVyPUe4MlAxPzNizszN NUP2Xpc2W0GQR1XS
UMC-11 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4OWlEPTB;N{iuNFg5PCEQvF2= NIXQbZBUSU6JRWK=
NCI-H226 NYLWfGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTd6LkGzNVUh|ryP NUPleGJFW0GQR1XS
IGROV-1 M{C5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzCOmk3UUN3ME23PE42PTVizszN NHyz[VBUSU6JRWK=
BHY NWfjdlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnRTnZKSzVyPUe5MlU6PiEQvF2= NXu2[o1vW0GQR1XS
MKN45 M{XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13NZWlEPTB;OECuN|E4PCEQvF2= MUXTRW5ITVJ?
IA-LM MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LocmlEPTB;OECuN|UyOSEQvF2= MYLTRW5ITVJ?
WM-115 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\rPGlEPTB;OEGuOFEyPCEQvF2= NGC0XJlUSU6JRWK=
VMRC-RCZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W3SWlEPTB;OEGuOFQzPSEQvF2= M17jd3NCVkeHUh?=
NCI-H2291 NFf1[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPYTWM2OD16MT62PFQzKM7:TR?= MnXhV2FPT0WU
MCF7 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr6eHpvUUN3ME24N{4zQDl5IN88US=> M{ntUXNCVkeHUh?=
639-V NFXKXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4O41VUUN3ME24OE43OTJ7IN88US=> MkXUV2FPT0WU
RT4 NFTwUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGwTWM2OD16NT6yOFA{KM7:TR?= NGPycWdUSU6JRWK=
NCI-H2405 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ldVhwUUN3ME24OU4zQTl5IN88US=> MV;TRW5ITVJ?
CAL-33 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq4eFFKSzVyPUi1MlY{OTVizszN MX3TRW5ITVJ?
BT-549 NUPLTYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rzXWlEPTB;OEWuPVM5OiEQvF2= MXfTRW5ITVJ?
HT-1197 NY[4OpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTh6LkGwO|ch|ryP NWP1[WptW0GQR1XS
G-361 M1foc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTaTWM2OD16OD6xOFc1KM7:TR?= M1LJb3NCVkeHUh?=
LS-411N M1LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrtTWM2OD16OT6zN|g5KM7:TR?= NF\ld|JUSU6JRWK=
HT-144 NGrHdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LzbWlEPTB;OEmuOVk6OiEQvF2= M{\ncXNCVkeHUh?=
DJM-1 NXTye4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHrTWM2OD16OT64PFQ2KM7:TR?= NWjYPYE4W0GQR1XS
CAL-12T Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHPZpkzUUN3ME25NE44QDl3IN88US=> Mn:0V2FPT0WU
MKN7 NW\hNolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnruTWM2OD17MT6zOVUyKM7:TR?= NIXMZnZUSU6JRWK=
HuP-T3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTl4LkGwNFQh|ryP M4HYN3NCVkeHUh?=
SK-MG-1 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmwTWM2OD17Nj6xN|Q5KM7:TR?= NHHufXBUSU6JRWK=
NCI-H2347 NIDmO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTl6LkGwOFIh|ryP NUXpeHJYW0GQR1XS
SW872 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1zMECuOFU3KM7:TR?= MV3TRW5ITVJ?
COLO-829 M3\jZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFyMD61OVMh|ryP M1PQcnNCVkeHUh?=
MC-IXC MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzrUoo1UUN3ME2xNFAvPjF3IN88US=> M2f1eHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID